Epigenetic remodeling via HDAC6 inhibition amplifies anti-tumoral immune responses in myeloid leukemia cells - PubMed
4 days ago
- #immunotherapy
- #HDAC6
- #myeloid leukemia
- HDAC6 inhibition impairs myeloid leukemia progression in vivo but not in vitro.
- HDAC6 loss upregulates immune-related modulators like RNase T2 in myeloid leukemia cells.
- Pharmacological HDAC6 inhibition increases RNase T2 expression via enhanced chromatin accessibility.
- HDAC6 inhibition enhances CD8+ T cell activation and restricts myeloid leukemia growth in mice.
- HDAC6 inhibitors synergize with Cytarabine and Clofarabine in myeloid leukemia cells.
- HDAC6 represents a promising target for myeloid leukemia therapy by boosting immune response and chemosensitivity.